EGFR and non-small cell lung carcinoma: NSCLC patients harboring activating mutations in epidermal growth factor receptor (EGFR), such as exon 19 deletions (Del 19) or L858R, show significant benefit with treatment of EGFR-tyrosine kinase inhibitors (EGFR-TKIs) [2–4].